Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

Matthew D. Hellmann, MD
Published: Wednesday, Jul 12, 2017



Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.

The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
 


Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.

The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x